Outside Links

The Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) logo

Program Goals

  • Overall
  • Clinical Research Project 1
  • Clinical Research Project 2
  • Pilot/Demonstration Clinical Research
  • Career Development & Training
  • Patient Advocacy
  • Industry Collaboration
    • Improve the lives of individuals with eosinophilic gastrointestinal disorders
    • Facilitate research on eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), and eosinophilic colitis (EC) through the development of a Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)
    • Establish a EGID Patient Contact Registry
    • Develop and maintain a website with information for scientists, health care providers, patients, and professional organizations
    • Determine the correlation of clinical outcome measures (COMs) and patient-reported outcomes (PROs) with the histological disease activity as measured by mucosal eosinophil counts
    • Develop a new gold standard for EoE, EG, and/or EC diagnosis and monitoring
    • Determine the correlation of the molecular profile for EoE, EG, and EC with COMs and mucosal eosinophilia
    • Optimize treatment of EoE with readily available therapies (diet and steroids)
    • Develop a personalized medicine approach based on biomarker analysis that can predict the best treatment for individual patients
    • Evaluate the efficacy of different restricted diets and determine whether patients who experience diet failure remain responsive to swallowed glucocorticoids (SGC) therapy
    • Support new ideas that have potential to create and/or change paradigms concerning EoE, EG, and EC
    • Train new investigators in clinical and translational research, enhancing the likelihood of academic success for the investigators in training
    • Enable CEGIR Trainees to become independent clinical and/or translational investigators
    • Aid CEGIR Trainees in developing a broad understanding of the basic, translational, and clinical science pertinent to the immunobiology, pathogenesis, and genetics of EoE, EG, and EC via didactic instruction
    • Facilitate CEGIR Trainee networking and integration in the EoE, EG, and EC research community

  • In collaboration with our partner Patient Advocacy Groups (PAGs):

    • Develop efficient pathways to communicate the latest clinical and research developments to patients and their families (via websites, social media, newsletters, conferences, contact registries)
    • Offer a forum for the collection and dissemination of patient and family perspectives and priorities
    • Offer public educational initiatives to raise awareness of and quality of care for eosinophilic GI diseases
    • Partner with industry in order to improve the lives of patients with EGIDs, including conducting clinical trials

CEGIR is dedicated to improving the lives of individuals with eosinophilic gastrointestinal disorders through innovative research, clinical expertise and education via collaborations between scientists, health care providers, patients, and professional organizations. The disorders CEGIR focuses on are eosinophilic esophagitis (EoE),

Eosinophilic gastritis (EG) and eosinophilic colitis (EC). The team has a multidisciplinary approach and integrates expertise in pediatric and adult clinical specialties, including gastroenterology, allergy, immunology and pathology. Funded by the National Institutes of Health (NIH), CEGIR is part of the Rare Diseases Clinical Research Network (RDCRN).

CURED both supports and is a part of the Consortium of Eosinophilic Gastrointestinal Researchers (CEGIR). CEGIR was founded in Fall 2014 with an NIH grant (U54 AI117804) and is believed to be the first to establish a network focusing on the three distinct diseases of eosinophilic esophagitis, eosinophilic gastritis, and eosinophilic colitis. CEGIR furthers research and clinical expertise, trains clinical investigators, supports pilot clinical research projects, and provides access to information related to eosinophilic disorders for basic and clinical researchers, physicians, patients, and the lay public.

The grant is funded by the Office of Rare Diseases Research, which is part of the NIH’s National Center for Advance Translational Studies, as part of the Rare Disease Research Network. This award is co-funded by the National Center for Advancing Translational Sciences, National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute of Allergy and Infectious Diseases. CURED is one of the patient advocacy organizations that contributes meaningfully by leading from within CEGIR and also donates $25 thousand to CEGIR’s initiatives. Coinciding with Rare Disease Day® 2015.